Key Points
- iRadimed CEO Roger Susi sold 5,000 shares on May 18 at an average price of $87.51, totaling $437,550. The sale was made under a pre-arranged Rule 10b5-1 plan, and Susi still holds 2.175 million shares.
- The company recently reported better-than-expected quarterly results, with EPS of $0.49 versus $0.46 expected and revenue of $21.98 million versus $21.32 million forecast. iRadimed also issued guidance for FY 2026 and Q2 2026.
- Despite the insider sale, Wall Street sentiment remains positive: analysts currently rate the stock “Buy” on average with a $120 price target, and the company recently declared a quarterly dividend of $0.20 per share.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $87.88, for a total transaction of $219,700.00. Following the completion of the sale, the chief executive officer owned 2,172,500 shares of the company's stock, valued at $190,919,300. This trade represents a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Stock Up 3.5%
Shares of NASDAQ IRMD opened at $90.40 on Thursday. The firm has a 50-day simple moving average of $93.03 and a 200-day simple moving average of $95.01. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of 49.40 and a beta of 0.90. iRadimed Corporation has a 52 week low of $50.88 and a 52 week high of $107.90.
iRadimed (NASDAQ:IRMD - Get Free Report) last issued its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The business had revenue of $21.98 million during the quarter, compared to analysts' expectations of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, equities research analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.
iRadimed Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed's dividend payout ratio is currently 43.72%.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of IRMD. CWM LLC boosted its stake in iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock worth $39,000 after buying an additional 211 shares during the period. Quarry LP purchased a new position in iRadimed during the third quarter worth about $40,000. Farther Finance Advisors LLC boosted its stake in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock worth $43,000 after buying an additional 397 shares during the period. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after buying an additional 495 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in shares of iRadimed in the third quarter valued at approximately $47,000. Hedge funds and other institutional investors own 92.34% of the company's stock.
Wall Street Analyst Weigh In
IRMD has been the subject of a number of analyst reports. Roth Mkm reissued a "buy" rating and issued a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th. Lake Street Capital reaffirmed a "buy" rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Weiss Ratings raised shares of iRadimed from a "buy (b-)" rating to a "buy (b)" rating in a research note on Wednesday, May 6th. Finally, Freedom Capital raised shares of iRadimed to a "strong-buy" rating in a research note on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $120.00.
Get Our Latest Stock Analysis on iRadimed
About iRadimed
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
